科源制药
(301281)
| 流通市值：43.37亿 | | | 总市值：43.37亿 |
| 流通股本：1.08亿 | | | 总股本：1.08亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 482,534,433.91 | 331,466,454.4 | 161,302,912.39 | 398,227,849.61 |
| 营业收入 | 482,534,433.91 | 331,466,454.4 | 161,302,912.39 | 398,227,849.61 |
| 二、营业总成本 | 388,566,158.51 | 262,042,515.83 | 128,319,432.51 | 363,809,681.93 |
| 营业成本 | 216,208,139.33 | 146,817,718.55 | 68,394,922.69 | 185,422,943.6 |
| 税金及附加 | 6,287,052.24 | 3,844,452.65 | 1,613,960.38 | 4,838,995.12 |
| 销售费用 | 95,586,157.36 | 69,501,803.8 | 38,957,002.19 | 80,614,434.06 |
| 管理费用 | 49,820,675.09 | 29,912,512.53 | 13,443,407.52 | 51,633,337.02 |
| 研发费用 | 19,024,577.43 | 11,158,081.5 | 5,719,905.44 | 42,351,346.09 |
| 财务费用 | 1,639,557.06 | 807,946.8 | 190,234.29 | -1,051,373.96 |
| 其中:利息费用 | 1,097,793.79 | 458,074.24 | 59,451.43 | 16,570.64 |
| 其中:利息收入 | 553,276.3 | 424,921.29 | 205,038.84 | 1,092,374.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 491,917.81 | 163,972.6 | - | - |
| 加:投资收益 | 829,420.81 | 618,084.02 | 600,000 | 5,925,403.13 |
| 资产处置收益 | - | - | - | 303,640.29 |
| 资产减值损失(新) | -4,197,705.4 | -3,799,032.82 | 385,404.68 | -17,717,169 |
| 信用减值损失(新) | -5,229,983.98 | -4,498,861.31 | -3,620,228.95 | -1,759,393.68 |
| 其他收益 | 4,734,902.35 | 3,691,664.99 | 3,052,191.92 | 11,216,044.63 |
| 四、营业利润 | 90,596,826.99 | 65,599,766.05 | 33,400,847.53 | 32,386,693.05 |
| 加:营业外收入 | 472,217.04 | 471,887.07 | 71,806.47 | 1,182,986.48 |
| 减:营业外支出 | -6,457,901.97 | -6,583,846.75 | 779,971.24 | 16,791,481.6 |
| 五、利润总额 | 97,526,946 | 72,655,499.87 | 32,692,682.76 | 16,778,197.93 |
| 减:所得税费用 | 10,689,412.95 | 8,184,883.18 | 2,156,610.76 | 401,646.81 |
| 六、净利润 | 86,837,533.05 | 64,470,616.69 | 30,536,072 | 16,376,551.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 86,837,533.05 | 64,470,616.69 | 30,536,072 | 16,376,551.12 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 85,343,514.52 | 64,692,066.26 | 30,073,425.23 | 16,552,986.82 |
| 少数股东损益 | 1,494,018.53 | -221,449.57 | 462,646.77 | -176,435.7 |
| 扣除非经常损益后的净利润 | 75,163,335.95 | 55,908,542.92 | 28,426,907.99 | 20,973,760.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.79 | 0.6 | 0.28 | 0.15 |
| (二)稀释每股收益 | 0.79 | 0.6 | 0.28 | 0.15 |
| 九、综合收益总额 | 86,837,533.05 | 64,470,616.69 | 30,536,072 | 16,376,551.12 |
| 归属于母公司股东的综合收益总额 | 85,343,514.52 | 64,692,066.26 | 30,073,425.23 | 16,552,986.82 |
| 归属于少数股东的综合收益总额 | 1,494,018.53 | -221,449.57 | 462,646.77 | -176,435.7 |
| 公告日期 | 2026-10-26 | 2026-08-27 | 2026-04-24 | 2026-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |